Verrica Pharmaceuticals (VRCA) News Today $0.42 -0.02 (-4.20%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.43 +0.01 (+1.43%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of DirectorsApril 4 at 12:37 AM | msn.comVerrica Pharmaceuticals Appoints Dr. Corcoran as DirectorApril 2 at 5:39 PM | tipranks.comVerrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of DirectorsApril 2 at 4:05 PM | globenewswire.comVerrica Pharmaceuticals to Present at Needham Healthcare ConferenceApril 2 at 6:53 AM | msn.comHarmony, Lungpacer, Verrica and Arbutus make C-suite hiresApril 1 at 1:15 AM | bizjournals.comVerrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comVerrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical OfficerMarch 28, 2025 | msn.comVerrica Pharmaceuticals appoints Rosenberg as CMOMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical OfficerMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.March 26, 2025 | globenewswire.comVerrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline ProgressMarch 13, 2025 | msn.comRBC Capital Remains a Hold on Verrica Pharmaceuticals (VRCA)March 12, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call TranscriptMarch 11, 2025 | seekingalpha.comVerrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c)March 11, 2025 | markets.businessinsider.comVerrica Pharmaceuticals files $150M mixed securities shelfMarch 11, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue EstimatesMarch 11, 2025 | msn.comVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025March 3, 2025 | globenewswire.comVerrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | msn.comVerrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in BostonFebruary 25, 2025 | globenewswire.comVerrica Pharmaceuticals announces presentation of three posters, data on VP-315January 21, 2025 | markets.businessinsider.comVerrica reports high response rate in skin cancer studyJanuary 21, 2025 | msn.comNeedham Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)December 22, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline DevelopmentDecember 20, 2024 | msn.comVerrica Provides Business and Operational UpdateDecember 20, 2024 | markets.businessinsider.comVerrica Pharmaceuticals provides update on new commerical strategy for YCANTHDecember 20, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Reports Increased Demand for YCANTH with New Single Applicator Configuration Coming in 2025December 20, 2024 | quiverquant.comVerrica Pharmaceuticals Grants Stock Option to New COO David ZawitzDecember 12, 2024 | msn.comVerrica Pharmaceuticals Appoints New Chief Operating OfficerDecember 9, 2024 | tipranks.comVerrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 9, 2024 | globenewswire.comNew Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208December 7, 2024 | msn.comVerrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in JapanDecember 6, 2024 | globenewswire.comChester County firm expects to raise $42M after trimming staff and naming new CEONovember 23, 2024 | bizjournals.comVerrica Pharmaceuticals 44.96M share Spot Secondary priced at $0.89November 22, 2024 | markets.businessinsider.comVerrica Pharmaceuticals prices 44.96M shares at 89c in public offeringNovember 21, 2024 | markets.businessinsider.comVerrica Pharmaceuticals stock dips after pricing $42M securities offeringNovember 21, 2024 | msn.comVerrica Announces Pricing of $42.0 Million Public OfferingNovember 21, 2024 | globenewswire.comVerrica Pharmaceuticals announces common stock offering, no amount givenNovember 21, 2024 | markets.businessinsider.comVerrica Announces Proposed Public OfferingNovember 20, 2024 | globenewswire.comHold Rating on Verrica Pharmaceuticals Amidst Restructuring and Financial UncertaintyNovember 7, 2024 | markets.businessinsider.comRBC Capital Downgrades Verrica Pharmaceuticals (VRCA)November 7, 2024 | msn.comHC Wainwright Downgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to NeutralHC Wainwright lowered shares of Verrica Pharmaceuticals from a "buy" rating to a "neutral" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comRBC downgrades Verrica Pharmaceuticals on ‘uncertain path’ forwardNovember 5, 2024 | markets.businessinsider.comVerrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results, Misses Estimates By $0.12 EPSVerrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) posted its earnings results on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of ($1.78) million for the quarter, compared to analysts' expectations of $7.53 million.November 5, 2024 | marketbeat.comVerrica Pharmaceuticals Undergoes Leadership and Financial RestructuringNovember 5, 2024 | markets.businessinsider.comVerrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Royal Bank of Canada to "Sector Perform"Royal Bank of Canada downgraded Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Tuesday.November 5, 2024 | marketbeat.comShares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational ChangesNovember 5, 2024 | marketwatch.comVerrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership TransitionNovember 5, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsOctober 30, 2024 | prnewswire.com Remove Ads Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address VRCA Media Mentions By Week VRCA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRCA News Sentiment▼0.120.61▲Average Medical News Sentiment VRCA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRCA Articles This Week▼72▲VRCA Articles Average Week Remove Ads Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NMRA News RAPT News AARD News LYEL News TARA News FULC News IVA News IKT News FDMT News IPHA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRCA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRCA Stock Free VRCA Stock Alerts